Free Trial
NASDAQ:BNTC

Benitec Biopharma Q2 2024 Earnings Report

Benitec Biopharma logo
$12.66 +0.15 (+1.20%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$12.68 +0.02 (+0.16%)
As of 08/14/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Benitec Biopharma EPS Results

Actual EPS
-$2.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Benitec Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Benitec Biopharma Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, February 13, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Benitec Biopharma's Q4 2025 earnings is scheduled for Thursday, September 25, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Benitec Biopharma Earnings Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
Benitec Biopharma price target raised to $20 from $18 at Citizens JMP
See More Benitec Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email.

About Benitec Biopharma

Benitec Biopharma (NASDAQ:BNTC) Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

View Benitec Biopharma Profile

More Earnings Resources from MarketBeat